Centene Corporation

CNC
Financial Analysis · Updated May 13, 2026 · Coverage 2026-Q2
Latest Q Revenue
$49.9B
Q1 2026 · +5% YoY
TTM ROIC
3.5%
FY2025 (adj.) · NOPAT (adj.) / Invested Capital · WACC ~8.5% · Moat spread +-5pp
Margin Profile
Gross 18%
Operating 1.75%
FCF 2.2%
FY2025
Net Debt
$4.0B
Cash $14.0B · Debt $18.0B · FY2024
Diluted Shares
493M
Q1 2026

Business Overview


ticker: CNC step: 01 generated: 2026-05-12 source: quick-research

Centene Corporation (CNC) — Business Overview

Business Description

Centene Corporation is one of the largest managed care organizations in the United States, operating as a Fortune 50 company that specializes in government-sponsored healthcare programs. Founded in 1984 and headquartered in St. Louis, Missouri, Centene primarily administers Medicaid managed care contracts across 31 states, while also serving Medicare Advantage and ACA Marketplace populations. The company acts as an intermediary between government payers and healthcare providers, earning a spread between premium revenue received and medical costs paid out.

Revenue Model

Centene earns premium revenues from government contracts (Medicaid, Medicare) and marketplace plans, then pays out medical claims to providers. The key profitability metric is the Health Benefits Ratio (HBR) — medical costs as a percentage of premium revenue. An HBR below 86–88% generates operating profit; above that, margins erode. Centene also earns service revenue from specialty subsidiaries (pharmacy benefit management, behavioral health, vision/dental). Revenue is very high in absolute terms ($160B+) but net margins are thin (~2–3%).

Products & Services

  • Medicaid Managed Care — Largest business: contracts with 31 states to manage Medicaid populations; ~59% of premium revenue
  • Medicare Advantage — Plans for seniors; growing focus segment
  • ACA Marketplace Plans — Individual and family health insurance through federal/state exchanges; historically ~$5–6B in premium revenue but contracting sharply in 2026
  • Specialty Services — Pharmacy benefit management (Envolve), behavioral health, home health, vision and dental services, and care management programs

Customer Base & Go-to-Market

Centene's primary "customers" are state and federal governments that award multi-year Medicaid managed care contracts. Individual members enroll through state programs or ACA exchanges. With ~13 million Medicaid members and several million Medicare/ACA members, Centene serves predominantly low-income, high-acuity populations. Contract renewals and rate-setting by state Medicaid agencies are the primary commercial lever.

Competitive Position

Centene is one of the top 3 Medicaid managed care companies alongside UnitedHealth Group and Molina Healthcare. Its competitive moat rests on: (1) deep state-by-state relationships and operational expertise in navigating complex Medicaid rules; (2) scale that enables lower administrative costs per member; and (3) a diversified network of specialty subsidiaries. The company has been under pressure since 2023–2025 due to post-COVID Medicaid redeterminations (which reduced membership by ~1.5M) and ACA Marketplace medical cost inflation.

Key Facts

  • Founded: 1984
  • Headquarters: St. Louis, Missouri
  • Employees: ~70,000+
  • Exchange: NYSE
  • Sector / Industry: Health Care / Managed Health Care
  • Market Cap: ~$20–25B (approximate, 2025–2026 after significant stock decline)

Financial Snapshot


ticker: CNC step: 04 generated: 2026-05-12 source: quick-research

Centene Corporation (CNC) — Financial Snapshot

Income Statement Summary

Metric FY2022 FY2023 FY2024 YoY
Revenue $144.5B $154.0B $163.1B +6%
Health Benefits Ratio (HBR) ~87.7% ~87.7% ~88.5%+
Operating Margin ~2.5% ~2.8% ~2.7%
Net Income ~$1.7B ~$2.7B $3.3B +22%
EPS (GAAP diluted) $2.07 ~$5.00 ~$6.30
EPS (adjusted diluted) $5.78 ~$7.00+ ~$7.50

Note: FY2025 was highly disrupted — ACA losses and Medicaid HBR pressure caused multiple guidance withdrawals and a large Q4 2025 loss. FY2025 full-year results showed ~$1.5B+ in challenges before partial recovery in Q1 2026.

Cash Flow & Balance Sheet (FY2024)

Metric Value
Operating Cash Flow ~$2.3B
Free Cash Flow ~$1.4B
Cash & Equivalents ~$14B
Total Debt ~$18B

Note: FY2022 FCF was $5.3B and FY2023 was $7.3B — FY2024 decline reflects Medicaid acuity and ACA cost pressures impacting earnings.

Key Ratios (approximate)

  • P/E (forward): ~8–10x | P/B: ~1.2x | FCF Yield: ~5–8%
  • Revenue Growth (FY2024): +6% | Net Margin: ~2%

Growth Profile

Centene has grown revenue rapidly through Medicaid contract wins and ACA marketplace expansion, but profitability has been highly volatile. The 2023–2025 period was defined by: (1) Medicaid redeterminations removing ~1.5M low-acuity members and raising average acuity/HBR; (2) ACA Marketplace adverse selection as enhanced subsidies fueled enrollment of high-cost members; and (3) state rate increases lagging medical cost inflation. ACA membership has already contracted sharply — from 5.5M at end-2025 to ~3.5M in Q1 2026 (-36%) as subsidy expirations drove healthier enrollees out.

Forward Estimates

  • FY2026: Revenue guidance reduced due to ACA membership losses; Medicaid HBR improvement is the key earnings driver; management expects "meaningful margin improvement and renewed adjusted EPS growth" — consensus cautious, Hold rating from 20 analysts

Deeper Financial Analysis

The fundamental tier adds 9 additional research dimensions for $CNC.

Revenue Breakdown
Segment revenue, geographic mix, product-line contribution margins, and cohort dynamics.
Financial Trends
Quarter-over-quarter momentum, leading indicators, and inflection point analysis.
Balance Sheet
Debt structure, liquidity runway, dilution risk, and working capital dynamics.
Capital Allocation
Buyback cadence, M&A appetite, dividend policy, and reinvestment priorities.
Returns on Capital (ROIC)
Multi-year ROIC vs. WACC, marginal returns on reinvestment, sales-to-invested-capital efficiency, and moat spread.
GET /api/v1/research/CNC/fundamental$1.00 · Bearer token required
Markdown: /stocks/cnc/financials/md · → thesis · → memo